
What is claimed is:

1. A compound of Formula (I) or a pharmaceutically acceptable salt thereof



(I)

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and


when M is N, each of X and Q are CH;

R^{15} is CH_3 or Cl;

R^{13} is H, F or C_1-C_4alkyl;

R^{14} is H, F or C_1-C_4alkyl;

HetA is



,





wherein

R^3 is H or C_1-C_4alkyl;

R^4 is selected from the group consisting of C_1-C_4alkyl, C_1-C_4perhaloalkyl and C_3-C_4cycloalkyl;

R^7 is H or C_1-C_4alkyl;

HetB is selected from the group consisting of


,

,

and

,

wherein

Z is selected from the group consisting of O, CH_2, NH and $N(CH_3)$;

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or $N(CH_3)$;


R^{16} is H or F;




R^{17} is H or F;


n is 0, 1 or 2;






R^{18} is selected from the group consisting of H, -CN, halo, $C(O)NH_2$, C_1-C_4alkyl and C_1-C_4perhaloalkyl;


R^{19} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;


$N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;  ;






 ;  ;  ; OC_1-C_6alkyl;


OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,






, and


;

-N(R^{38})C_1-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH_3, -N(R^{36})R^{37}, C_1-C_4alkyl ,  ,






and



; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH_2CH_2OH, -C(O)NH$CH_2CH_2OCH_2CH_2NH_2$, C(O)NH_2 and OH;

R^{20} is H or C_1-C_4alkyl;

R^{21} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{22} and R^{23} are taken together with the carbon to which they are attached to form

(a) the moiety , wherein R is selected from the group consisting of CH_2, NR^{38} and O, m is 0 or 1, and p is 0 or 1; or


(b) the moiety ;


$R^{22'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl, and


$R^{23'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl;


R^{24} is selected from the group consisting of H; CN; halo; C(O)NH_2;

$C(O)(NH)C_3$-C_4cycloalkyl; $N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;





;



;



;



; OC_1-C_6alkyl;


OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl;


,


,



,



,



,



and



;


$-N(R^{38})C_1$-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, $-OCH_3$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,


,


,


,


,



,





and








; and







C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of $-C(O)NHCH_2CH_2OH$, $-C(O)NHCH_2CH_2OCH_2CH_2NH_2$, $C(O)NH_2$ and OH;

R^{25} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;

N(R^{38})C_1-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;  ;

 ;  ;  ; OC_1-C_6alkyl;

OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,  ,  ,  ,  ,  and  ;

$-N(R^{38})C_1$-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, $-OCH_3$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,  ,  ,  ,  ,  and  ; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of $-C(O)NHCH_2CH_2OH$, $-C(O)NHCH_2CH_2OCH_2CH_2NH_2$, $C(O)NH_2$ and OH;

R^{26} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{27} is H or C_1-C_4alkyl;

R^{36} and R^{37} are independently selected from the group consisting of H and C_1-C_4alkyl;

R^{38} is H or C_1-C_4alkyl.

2. A compound as claimed in claim 1, wherein:

a) R^4 is C_1-C_4alkyl or C_1-C_4perhaloalkyl; or

b) R^4 is C_1-C_4perhaloalkyl; or

c) R^4 is C_1-C_2perhaloalkyl; or

d) R^4 is CF_3; or

e) R^4 is C_1-C_4perhaloalkyl, R^3 is C_1-C_4alkyl and R^7 is H; or

f) R^4 is C_1-C_2perhaloalkyl, R^3 is C_1-C_4alkyl and R^7 is H; or

g) R^4 is C_1-C_2perhaloalkyl, R^3 is C_1-C_2alkyl and R^7 is H; or

h) R^4 is C_1-C_2perhaloalkyl, R^3 is CH_3 and R^7 is H; or

i) R^4 is CF_3, R^3 is CH_3 and R^7 is H.

3. A compound as claimed in claim 1, wherein:

a) X is N; or

b) X is CH; or

c) R^{15} is CH_3; or

d) R^{15} is Cl; or

e) R^{13} is CH_3; or

f) R^{13} is CH_3 and R^{14} is H; or

g) R^{13} is CH_3 and R^{14} is CH_3; or

h) R^{13} is H and R^{14} is H.

4. A compound as claimed in claim 1, wherein:

a) R^4 is CF_3, R^3 is CH_3, R^7 is H and X is N; or

b) R^4 is CF_3, R^3 is CH_3, R^7 is H, X is N and R^{15} is CH_3; or

c) R^4 is CF_3, R^3 is CH_3, R^7 is H, X is N, R^{15} is CH_3, R^{13} is H and R^{14} is H; or


d) R^4 is CF_3, R^3 is CH_3, R^7 is H, X is N, R^{15} is CH_3, R^{13} is CH_3 and R^{14} is CH_3; or

e) R^4 is CF_3, R^3 is CH_3, R^7 is H and X is CH; or


f) R^4 is CF_3, R^3 is CH_3, R^7 is H, X is CH, and R^{15} is Cl.

5. A compound as claimed in claim 1, wherein HetB is:


a) selected from the group consisting of



,




and




; or

b) selected from the group consisting of




and




; or

c)




; or

d)




; or

e)




; or


f)



; or


g)




, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 

, wherein R is CH_2 or O, m is 0 or 1, and p is 0 or 1; or


h)




, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 

, wherein R is O, m is 0 or 1, and p is 0 or 1; or


i)




, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 

, wherein R is O, m is 1, and p is 1; or


j)




, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 

, wherein R is O, m is 1, p is 1, R^{13} is C_1-C_4alkyl, and R^{14} is C_1-C_4alkyl; or


k)




, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 


, wherein R is O, m is 1, p is 1, R^{13} is CH_3, and R^{14} is CH_3.

6. A compound as claimed in claim 1, wherein:


a) HetB is 


,R^4 is CF_3, R^3 is CH_3, R^7 is H, X is CH, R^{15} is CH_3, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 


, wherein R is O, m is 1, p is 1, R^{13} is CH_3, and R^{14} is CH_3; or

b) HetB is 


,R^4 is CHF_2, R^3 is CH_3, R^7 is H, X is CH, Q is CH, M is CH, W is N, R^{24} is H, R^{21} is CH_3, R^{15} is CH_3, R^{13} is CH_3, R^{14} is CH_3, and R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety  ; or


c) HetB is 

,R^4 is CF_3, R^3 is CH_3, R^7 is H, X is CH, R^{15} is CH_3, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 


, wherein R is O, m is 1, p is 1, R^{13} is CH_3, R^{14} is CH_3 and R^{24} is OC_2-C_4alkyl or OC_2-C_4alkyl is substituted with 

; or

d) HetB is 

, R^4 is cyclopropyl, R^3 is CH_3, R^7 is H, X is CH, Q is CH, M is CH, R^{15} is CH_3, R^{22} and R^{23} are taken together with the carbon to which they are attached to form the moiety 


, wherein R is O, m is 1, p is 1, R^{13} is CH_3, and R^{14} is CH_3; or

e) R^{18} is OC_1-C_4alkyl substituted with one of -OH, -N(R^{36})R^{37} and 

; or

f) R^{18} is NHC_1-C_4alkyl substituted with one of OH and CH_3; or


g) R^{18} is C_1-C_4alkyl is substituted with one of $C(O)NHCH_2CH_2OH$ and OH; or

h) R^{24} is OC_1-C_4alkyl substituted with one of -OH, -N(R^{36})R^{37} and 

; or

i) R^{24} is NHC_1-C_4alkyl substituted with one of OH and CH_3; or

j) R^{24} is C_1-C_4alkyl is substituted with one of $C(O)NHCH_2CH_2OH$ and OH; or




k) R^{25} is OC_1-C_4alkyl substituted with one of -OH, -N(R^{36})R^{37} and 



; or










l) R^{25} is NHC_1-C_4alkyl substituted with one of OH and CH_3; or


m) R^{25} is C_1-C_4alkyl is substituted with one of $C(O)NHCH_2CH_2OH$ and OH.

7. A compound selected from the group consisting of



; 
; 
;



; 
;



;

;

;

;

;

;;

;

;

;
;



;









; and pharmaceutically acceptable salts thereof.

8. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

9. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

10. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

11. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

12. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

13. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

14. The compound of claim 7, wherein the compound is



or a pharmaceutically acceptable salt thereof.

15. The compound of claim 7, wherein the compound is




or a pharmaceutically acceptable salt thereof.

16. A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 1 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition, comprising an effective amount of at least one compound as claimed in claim 7 and a pharmaceutically acceptable excipient.

18. Use of a compound selected from the compounds of Formula (I) or a pharmaceutically acceptable salt thereof,



(I)

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and


when M is N, each of X and Q are CH;

R^{15} is CH_3 or Cl;

R^{13} is H, F or C_1-C_4alkyl;

R^{14} is H, F or C_1-C_4alkyl;

HetA is







wherein

R^3 is H or C_1-C_4alkyl;

R^4 is selected from the group consisting of C_1-C_4alkyl, C_1-C_4perhaloalkyl and C_3-C_4cycloalkyl;

R^7 is H or C_1-C_4alkyl;

HetB is selected from the group consisting of


,

,

and

,

wherein

Z is selected from the group consisting of O, CH_2, NH and $N(CH_3)$;

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or $N(CH_3)$;


R^{16} is H or F;




R^{17} is H or F;


n is 0, 1 or 2;






R^{18} is selected from the group consisting of H, -CN, halo, $C(O)NH_2$, C_1-C_4alkyl and C_1-C_4perhaloalkyl;


R^{19} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;


$N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;  ;






 ;  ;  ; OC_1-C_6alkyl;

OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,






, and


;

-N(R^{38})C_1-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH_3, -N(R^{36})R^{37}, C_1-C_4alkyl , ,






and



; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH_2CH_2OH, -C(O)NH$CH_2CH_2OCH_2CH_2NH_2$, C(O)NH_2 and OH;

R^{20} is H or C_1-C_4alkyl;

R^{21} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{22} and R^{23} are taken together with the carbon to which they are attached to form

(a) the moiety , wherein R is selected from the group consisting of CH_2, NR^{38} and O, m is 0 or 1, and p is 0 or 1; or





(b) the moiety ;

$R^{22'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl, and


$R^{23'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl;






R^{24} is selected from the group consisting of H; CN; halo; C(O)NH_2;

$C(O)(NH)C_3$-C_4cycloalkyl; $N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;





; OC_1-C_6alkyl;


OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl;







,


,

,

,

,

and


;

$-N(R^{38})C_1$-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, $-OCH_3$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,



,





,

,

,

,

and








; and







C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of $-C(O)NHCH_2CH_2OH$, $-C(O)NHCH_2CH_2OCH_2CH_2NH_2$, $C(O)NH_2$ and OH;

R^{25} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;

$N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;  ;

 ;  ;  ; OC_1-C_6alkyl;

OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,  ,  ,  ,  ,  and  ;

$-N(R^{38})C_1$-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, $-OCH_3$, $-N(R^{36})R^{37}$, C_1-C_4alkyl,  ,  ,  ,  ,  ,  and  ; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of $-C(O)NHCH_2CH_2OH$, $-C(O)NHCH_2CH_2OCH_2CH_2NH_2$, $C(O)NH_2$ and OH;

R^{26} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{27} is H or C_1-C_4alkyl;

R^{36} and R^{37} are independently selected from the group consisting of H and C_1-C_4alkyl;

R^{38} is H or C_1-C_4alkyl

in the manufacture of a medicament for treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, wherein an effective amount of at least one of the compound is to be administered to the subject in need thereof.

19. Use of the compound as claimed in claim 7 in the manufacture of a medicament for the treatment of a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, wherein an effective amount of at least one of the compound is to be administered to the subject in need thereof.

20. The use of claim 18, wherein the disease, disorder or medical condition is selected from the group consisting of MS, PD, AD, ALS, CKD, pulmonary arterial hypertension, atherosclerosis, hypertension, heart failure, acute coronary syndrome, myocardial infarction, cardiac arrhythmias, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction and diabetic cardiomyopathy, COPD, asthma, pulmonary fibrosis , cigarette smoke-induced emphysema, IBD, CD , UC, psoriasis, age-related macular degeneration, Fuchs Endothelial Corneal Dystrophy, uveitis, type-1 diabetes, type-2 diabetes, insulin resistance, sepsis-induced acute kidney injury, acute kidney injury, preeclampsia, acute mountain sickness, dermatitis and topical effects of radiation, immunosuppression due to radiation exposure, non-alcoholic steatohepatitis, viral hepatitis, cirrhosis, and a toxin-induced liver disease such as acetaminophen-induced hepatic disease.

21. The use of claim 20, wherein the disease, disorder or medical condition is selected from the group consisting of IBD, CD and UC.

22. The use of claim 21, wherein the disease, disorder or medical condition is CD.

23. The use of claim 21, wherein the disease, disorder or medical condition is UC.


24. The use of claim 19, wherein the disease, disorder or medical condition is selected from the group consisting of MS, PD, AD, ALS, CKD, pulmonary arterial hypertension, atherosclerosis, hypertension, heart failure, acute coronary syndrome, myocardial infarction, cardiac arrhythmias, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction and diabetic cardiomyopathy, COPD, asthma, pulmonary fibrosis , cigarette smoke-induced emphysema, IBD, CD , UC, psoriasis, age-related macular degeneration, Fuchs Endothelial Corneal Dystrophy, uveitis, type-1 diabetes, type-2 diabetes, insulin resistance, sepsis-induced acute kidney injury, acute kidney injury, preeclampsia, acute mountain sickness, dermatitis and topical effects of radiation, immunosuppression due to radiation exposure, non-alcoholic steatohepatitis, viral hepatitis, cirrhosis, and a toxin-induced liver disease such as acetaminophen-induced hepatic disease.

25. The use of claim 19, wherein the disease, disorder or medical condition is selected from the group consisting of IBD, CD and UC.

26. The use of claim 19, wherein the disease, disorder or medical condition is CD.


27. The use of claim 19, wherein the disease, disorder or medical condition is UC.

28. The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

29 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

30 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

31 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

32 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

33 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

34 . The use of Claim 19, wherein the compound is




or a pharmaceutically acceptable salt thereof.

35 . The use of Claim 19, wherein the compound is



or a pharmaceutically acceptable salt thereof.

36. A compound of Formula (I) or a pharmaceutically acceptable salt thereof,



(I)

wherein

X is CH or N;

Q is CH or N;

M is CH or N;

wherein

when X is N, each of Q and M is CH;

when Q is N, each of X and M is CH; and


when M is N, each of X and Q are CH;

R^{15} is CH_3 or Cl;

R^{13} is H, F or C_1-C_4alkyl;

R^{14} is H, F or C_1-C_4alkyl;

HetA is



,


wherein

R^3 is H or C_1-C_4alkyl;


R^4 is selected from the group consisting of C_1-C_4alkyl, C_1-C_4perhaloalkyl and C_3-C_4cycloalkyl;

R^7 is H or C_1-C_4alkyl;


HetB is selected from the group consisting of




,



,



and



,

wherein

Z is selected from the group consisting of O, CH_2, NH and $N(CH_3)$;

T is CH or N;

Y is CH or N;

W is CH or N;

V is O or $N(CH_3)$;


R^{16} is H or F;




R^{17} is H or F;







n is 0, 1 or 2;







R^{18} is selected from the group consisting of H, -CN, halo, $C(O)NH_2$, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{19} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;

N(R^{38})C_1-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;  ;

 ;  ;  ; OC_1-C_6alkyl;

OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH_3, -$O(CH_2)_3OH$, -N(R^{36})R^{37}, C_1-C_4alkyl,  ,  ,  ,  ,  ,  , and  ;


-N(R^{38})C_1-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH_3, -N(R^{36})R^{37}, C_1-C_4alkyl ,  ,  ,  ,  ,  ,  and  ; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)$NHCH_2CH_2OH$, -C(O)$NHCH_2CH_2OCH_2CH_2NH_2$, C(O)NH_2 and OH;

R^{20} is H or C_1-C_4alkyl;

R^{21} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{22} and R^{23} are taken together with the carbon to which they are attached to form

(a) the moiety , wherein R is selected from the group consisting of CH_2, NR^{38} and O, m is 0 or 1, and p is 0 or 1; or





(b) the moiety ;








$R^{22'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl, and








$R^{23'}$ is selected from the group consisting of H, C_1-C_4alkyl and C_3-C_4cycloalkyl;

R^{24} is selected from the group consisting of H; CN; halo; $C(O)NH_2$;

$C(O)(NH)C_3$-C_4cycloalkyl; $N(R^{38})C_1$-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl;


; ; ; ; OC_1-C_6alkyl;




OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, $-OCH_3$, $-O(CH_2)_3OH$, $-N(R^{36})R^{37}$, C_1-C_4alkyl; , , , , ,  and ;








$-N(R^{38})C_1$-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, $-OCH_3$, $-N(R^{36})R^{37}$, C_1-C_4alkyl, , , , , ,  and ; and








C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH$_2$CH$_2$OH, -C(O)NHCH$_2$CH$_2$OCH$_2$CH$_2$NH$_2$, C(O)NH$_2$ and OH;

R^{25} is selected from the group consisting of H; CN; halo; C(O)NH$_2$;

N(R^{38})C_1-C_6alkyl; C_1-C_4alkyl; C_1-C_4perhaloalkyl; ;

; ; ; OC_1-C_6alkyl;

OC_1-C_6alkyl substituted with one or two substituents selected from the group consisting of -OH, -OCH$_3$, -O(CH$_2$)$_3$OH, -N(R^{36})R^{37}, C_1-C_4alkyl, , , , , ,  and ;

-N(R^{38})C_1-C_6alkyl substituted with one or two substituents selected from the group consisting of OH, -OCH$_3$, -N(R^{36})R^{37}, C_1-C_4alkyl, , , , , ,  and ; and

C_1-C_4alkyl monosubstituted with a substituent selected from the group consisting of -C(O)NHCH$_2$CH$_2$OH, -C(O)NHCH$_2$CH$_2$OCH$_2$CH$_2$NH$_2$, C(O)NH$_2$ and OH;

R^{26} is selected from the group consisting of H, -CN, halo, C_1-C_4alkyl and C_1-C_4perhaloalkyl;

R^{27} is H or C_1-C_4alkyl;

R^{36} and R^{37} are independently selected from the group consisting of H and C_1-C_4alkyl;

R^{38} is H or C_1-C_4alkyl,

for use in the treatment of a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, wherein an effective amount of the compound is to be administered to the subject in need thereof.

37 . The compound as claimed in claim 7 for use in treating a subject suffering from or diagnosed with a disease, disorder, or medical condition associated with the KEAP1-Nrf2 interaction, wherein an effective amount of at least one of the compound is to be administered to the subject.